Crescent Biopharma

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu

Crescent Biopharmas vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Companys clinical-stage pipeline includes its lead program a PD-1 x VEGF bispecific antibody as well as novel antibody-drug conjugates. By leveraging mu